Sign In
Buy EVGN
$0.599
+0.0089 (+1.51%)
At Close: Jun 03, 2026
Biomica Reports Positive Preliminary Results in Animal Studies in Its Immuno-oncology Program
12:00pm, Tuesday, 12'th Nov 2019
Demonstrating Improved Anti-Tumor Activity Following Treatment with BMC 121 & BMC 127 REHOVOT, Israel , Nov. 12, 2019 /PRNewswire/ -- Biomica, an emerging biopharmaceutical company developing innovat
REHOVOT, Israel, Nov. 6, 2019 /PRNewswire/ -- Canonic, a wholly owned subsidiary of Evogene Ltd. (EVGN) (EVGN.TA) focused on the development of medical cannabis products, announces today the initiati
Evogene Reports Its Canonic Wholly-Owned Subsidiary Initiates Cultivation, Breeding Program Of Cannabis Varieties
12:00am, Wednesday, 06'th Nov 2019Evogene Financial Results for the Third Quarter of 2019 Earnings Announcement Schedule
11:00am, Wednesday, 23'rd Oct 2019
REHOVOT, Israel , Oct. 23, 2019 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading biotechnology company developing novel products for life science markets, announced today that it w
Biomica Reports Will Collaborate With Weizmann Institute To Develop Selective Treatment Against Antibiotic Resistant Bacteria
12:00am, Wednesday, 23'rd Oct 2019Biomica Announces Advancement to Pre-Clinical Studies in its Inflammatory Bowel Disease Program
11:00am, Wednesday, 02'nd Oct 2019
REHOVOT, Israel, Oct. 2, 2019 /PRNewswire/ -- Biomica, an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (EVGN) and (EVGN.TA
Lavie Bio, Evogene's Ag-Biologicals Subsidiary, Announces the Nomination of Industry Experts to its Board of Directors
11:00am, Wednesday, 11'th Sep 2019
The nomination of industry experts is expected to support the company's management in execution of its product development and commercialization roadmap REHOVOT, Israel , Sept. 11, 2019 /PRNewswire/ -
